Bioactive Macromolecule-mediated Biogenic FeONPs Attenuate Inflammation in Atherosclerotic Rat by Activating PI3K/Akt/eNOS Pathway.

IF 2.6 4区医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2024-09-23 DOI:10.2174/0113816128298009240828062231

Qing Du, Bo Chen, Xiaohan Yang, Hecheng Zhu, Syed Shams Ul Hassan, Qiang Liu

{"title":"Bioactive Macromolecule-mediated Biogenic FeONPs Attenuate Inflammation in Atherosclerotic Rat by Activating PI3K/Akt/eNOS Pathway.","authors":"Qing Du, Bo Chen, Xiaohan Yang, Hecheng Zhu, Syed Shams Ul Hassan, Qiang Liu","doi":"10.2174/0113816128298009240828062231","DOIUrl":null,"url":null,"abstract":"Introduction: Atherosclerosis refers to the thickening and hardening of artery walls. In our latest experiment, we utilized environmentally friendly techniques to produce multifunctional iron oxide nanoparticles (FeONPs) aimed at reducing inflammation in rats with atherosclerosis.Method: The formulation was synthesized using curcumin (as the potent bioactive molecule) and was characterized. We assessed the in vitro antioxidant capability of the formulation against DPPH free radicals. Additionally, we quantified the mRNA levels of eNOS, PI3K, and AKT using Real Time-Polymerase Chain Reaction (RT-PCR). We tested the therapeutic impact of the bioactive formulation on a Triton X-100-induced atherosclerosis mouse model.Results: The crystallinity and magnetic behavior confirmed the magnetic properties of the FeONPs. The DPPH assay exhibited the dose-dependent radical scavenging characteristics of FeONPs. In the animal experiments, significant upregulation of the studied genes was noticed in treated groups 2 and 3 compared to treated group 1. Moreover, the expression of PI3K/eNOS/Akt was greater in treated group 3 than in treated group 2. These results indicate a dose-dependent elevation in target gene expression.Conclusion: Nevertheless, the variation in gene expression between the negative control and the untreated control was not statistically significant (p > 0.05) across all genes.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128298009240828062231","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Atherosclerosis refers to the thickening and hardening of artery walls. In our latest experiment, we utilized environmentally friendly techniques to produce multifunctional iron oxide nanoparticles (FeONPs) aimed at reducing inflammation in rats with atherosclerosis.

Method: The formulation was synthesized using curcumin (as the potent bioactive molecule) and was characterized. We assessed the in vitro antioxidant capability of the formulation against DPPH free radicals. Additionally, we quantified the mRNA levels of eNOS, PI3K, and AKT using Real Time-Polymerase Chain Reaction (RT-PCR). We tested the therapeutic impact of the bioactive formulation on a Triton X-100-induced atherosclerosis mouse model.

Results: The crystallinity and magnetic behavior confirmed the magnetic properties of the FeONPs. The DPPH assay exhibited the dose-dependent radical scavenging characteristics of FeONPs. In the animal experiments, significant upregulation of the studied genes was noticed in treated groups 2 and 3 compared to treated group 1. Moreover, the expression of PI3K/eNOS/Akt was greater in treated group 3 than in treated group 2. These results indicate a dose-dependent elevation in target gene expression.

Conclusion: Nevertheless, the variation in gene expression between the negative control and the untreated control was not statistically significant (p > 0.05) across all genes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

生物活性大分子介导的生物铁ONP通过激活PI3K/Akt/eNOS通路减轻动脉粥样硬化大鼠的炎症。

导言动脉粥样硬化是指动脉壁的增厚和硬化。在最新的实验中，我们利用环保技术生产了多功能氧化铁纳米粒子（FeONPs），旨在减轻动脉粥样硬化大鼠的炎症反应：方法：使用姜黄素（作为强效生物活性分子）合成了配方，并对其进行了表征。我们评估了配方对 DPPH 自由基的体外抗氧化能力。此外，我们还使用实时聚合酶链式反应（RT-PCR）对 eNOS、PI3K 和 AKT 的 mRNA 水平进行了量化。我们测试了生物活性配方对 Triton X-100 诱导的动脉粥样硬化小鼠模型的治疗效果：结果：结晶度和磁性行为证实了 FeONPs 的磁性。DPPH 试验表明，FeONPs 具有剂量依赖性自由基清除特性。在动物实验中，与处理组 1 相比，处理组 2 和处理组 3 的研究基因明显上调，而且处理组 3 的 PI3K/eNOS/Akt 表达量高于处理组 2：尽管如此，在所有基因中，阴性对照组和未处理对照组之间的基因表达差异均无统计学意义（P > 0.05）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current pharmaceutical design 医学-药学

CiteScore

6.30

自引率

0.00%

发文量

302

审稿时长

2 months

期刊介绍： Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.